Biopharmaceutical

Global Blood Therapeutics

$49.92
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.15 (+0.30%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell GBT and other stocks, options, and ETFs commission-free!

About GBT

Global Blood Therapeutics, Inc. Common Stock, also called Global Blood Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. The listed name for GBT is Global Blood Therapeutics, Inc. Common Stock.

CEO
Ted W. Love
Employees
352
Headquarters
South San Francisco, California
Founded
2011
Market Cap
3.04B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.07M
High Today
$50.68
Low Today
$49.10
Open Price
$49.10
Volume
1.35M
52 Week High
$87.54
52 Week Low
$36.49

Collections

GBT Earnings

-$1.59
-$1.06
-$0.53
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 24, After Hours

You May Also Like

DMS+
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure